Page 990 - Clinical Immunology_ Principles and Practice ( PDFDrive )

956 ParT SEvEN Organ-Specific Inflammatory Disease

progressive or severe disease will also be helpful in identifying reconstitution in patients with advanced human immunodeficiency virus
patients for early intervention. The development of anti–TSH­R– (HIV) disease. Medicine (Baltimore) 2005;84:98–106.
blocking antibodies as a therapeutic agent for hyperthyroid GD 14. Smith BR, Bolton J, Young S, et al. A new assay for thyrotropin receptor
seems likely. These agents might have a role in patients unlikely autoantibodies. Thyroid 2004;14:830–5.
to gain medical remission from thionamide antithyroid drugs 15. Czarnocka B. Thyroperoxidase, thyroglobulin, Na(+)/I(−) symporter,
pendrin in thyroid autoimmunity. Front Biosci 2011;16:783–802.
or in those for whom rapid control of hyperthyroidism is desir­ 16. Costagliola S, Bonomi M, Morgenthaler NG, et al. Delineation of the
able. Small­molecule TSH­R antagonists may also come to the discontinuous­conformational epitope of a monoclonal antibody
clinic, with a similar role. displaying full in vitro and in vivo thyrotropin activity. Mol Endocrinol
2004;18:3020–34.
Please check your eBook at https://expertconsult.inkling.com/ 17. McLachlan SM, Rapoport B. Thyroid peroxidase as an autoantigen.
for self­assessment questions. See inside cover for registration Thyroid 2007;17:939–48.
details. 18. Hegedus L. Treatment of Graves’ hyperthyroidism: evidence­based and
emerging modalities. Endocrinol Metab Clin North Am 2009;38:355–71,
ix.
REFERENCES 19. Perros P, Dayan CM, Dickinson AJ, et al. Management of patients with
Graves’ orbitopathy: initial assessment, management outside specialised
1. Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease
in a community: the Whickham survey. Clin Endocrinol (Oxf) centres and referral pathways. Clin Med (Lond) 2015;15:173–8.
1977;7:481–93. 20. Bahn RS. Graves’ ophthalmopathy. N Engl J Med 2010;362:726–38.
2. Laurberg P, Pedersen KM, Vestergaard H, et al. High incidence of 21. Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of
multinodular toxic goitre in the elderly population in a low iodine intake mild Graves’ orbitopathy. NEJM 2011;364:1920–31.
area vs. high incidence of Graves’ disease in the young in a high iodine 22. Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the
intake area: comparative surveys of thyrotoxicosis epidemiology in European Group on Graves’ orbitopathy (EUGOGO) on management of
East­Jutland Denmark and Iceland. J Intern Med 1991;229:415–20. GO. Eur J Endocrinol 2008;158:273–85.
3. Brix TH, Kyvik KO, Christensen K, et al. Evidence for a major role of 23. Salvi M, Campi I. Medical treatment of Graves’ orbitopathy. Horm Metab
heredity in Graves’ disease: a population­based study of two Danish twin Res 2015;47:779–88.
cohorts. J Clin Endocrinol Metab 2001;86:930–4. 24. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of
4. Vaidya B, Kendall­Taylor P, Pearce SH. The genetics of autoimmune thyroid disorders in the community: a twenty­year follow­up of the
thyroid disease. J Clin Endocrinol Metab 2002;87:5385–97. Whickham Survey. Clin Endocrinol (Oxf) 1995;43:55–68.
5. Eschler DC, Hasham A, Tomer Y. Cutting edge: the etiology of 25. Agate L, Mariotti S, Elisei R, et al. Thyroid autoantibodies and thyroid
autoimmune thyroid diseases. Clin Rev Allergy Immunol 2011;41:190–7. function in subjects exposed to Chernobyl fallout during childhood:
6. Ueda H, Howson JM, Esposito L, et al. Association of the T­cell evidence for a transient radiation­induced elevation of serum thyroid
regulatory gene CTLA4 with susceptibility to autoimmune disease. antibodies without an increase in thyroid autoimmune disease. J Clin
Nature 2003;423(6939):506–11. Endocrinol Metab 2008;93:2729–36.
7. Velaga MR, Wilson V, Jennings CE, et al. The codon 620 tryptophan allele 26. Imaizumi M, Usa T, Tominaga T, et al. Radiation dose­response
of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant relationships for thyroid nodules and autoimmune thyroid diseases in
of Graves’ disease. J Clin Endocrinol Metab 2004;89:5862–5. Hiroshima and Nagasaki atomic bomb survivors 55­58 years after
8. Brent GA. Environmental exposures and autoimmune thyroid disease. radiation exposure. JAMA 2006;295:1011–22.
Thyroid 2010;20:755–61. 27. Quaratino S, Badami E, Pang YY, et al. Degenerate self­reactive human
9. Vestergaard P. Smoking and thyroid disorders—a meta­analysis. T­cell receptor causes spontaneous autoimmune disease in mice. Nat Med
Eur J Endocrinol 2002;146:153–61. 2004;10:920–6.
10. Cawood TJ, Moriarty P, O’Farrelly C, et al. Smoking and 28. Pearce SHS, Brabant G, Duntas LH, et al. 2013 ETA guideline:
thyroid­associated ophthalmopathy: a novel explanation of the biological management of subclinical hypothyroidism. Eur Thyroid J 2013;2:215–28.
link. J Clin Endocrinol Metab 2007;92:59–64. 29. Landek­Salgado MA, Gutenberg A, Lupi I, et al. Pregnancy, postpartum
11. Winsa B, Adami HO, Bergström R, et al. Stressful life events and Graves’ autoimmune thyroiditis, and autoimmune hypophysitis: intimate
disease. Lancet 1991;338:1475–9. relationships. Autoimmun Rev 2010;9:153–7.
12. Matos­Santos A, Nobre EL, Costa JG, et al. Relationship between the 30. De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid
number and impact of stressful life events and the onset of Graves’ dysfunction during pregnancy and postpartum: an Endocrine Society
disease and toxic nodular goitre. Clin Endocrinol (Oxf) 2001;55:15–19. clinical practice guideline. J Clin Endocrinol Metab 2012;97:2543–65.
13. Chen F, Day SL, Metcalfe RA, et al. Characteristics of autoimmune 31. Davies TF, Ando T, Lin RY, et al. Thyrotropin receptor­associated diseases:
thyroid disease occurring as a late complication of immune from adenomata to Graves’ disease. J Clin Invest 2005;115:1972–83.